Hirschsprung's disease
Conditions
Interventions
Normal infants and young children (control group):None
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for patients with HSCR (1) Confirmed diagnosis of HSCR: Children diagnosed with HSCR based on preoperative barium enema, anorectal manometry, and postoperative pathological examination. (2) Pathological specimens: Children who underwent laparoscopic or robot-assisted radical pull-through surgery for Hirschsprung disease, from whom intraoperative tissue samples could be clearly obtained from both the stenotic segment (aganglionic segment) and the anastomotic segment (normally ganglionated segment). 2. Inclusion criteria for normal infants and young children (1) Normal intestinal tissue obtained during surgery: Normal intestinal tissue obtained from children undergoing surgery for intussusception or stoma closure after NEC. (2) Age matching: The age range was matched to that of the HSCR group. (3) Health status: No known gastrointestinal diseases, no history or suspected symptoms of HSCR, no history of intestinal surgery, and normal growth and development.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients with HSCR 1. Atypical or complex HSCR: Total colonic aganglionosis or HSCR associated with other complex intestinal malformations, such as intestinal malrotation, gastroschisis, omphalocele, or related congenital anomalies. 2. Severe systemic diseases: Including severe congenital heart disease, active systemic infection, inherited metabolic disorders, known immunodeficiency disorders, malignant tumors, or other serious systemic illnesses. 3. Severe intestinal inflammation or infection: Preoperatively confirmed enterocolitis or necrotizing enterocolitis. 4. Neurological disorders: Other known neurogenic diseases that may affect the enteric nervous system. Exclusion criteria for normal infants and young children 1. Presence of other congenital malformations. 2. Severe systemic diseases: Including severe congenital heart disease, active systemic infection, inherited metabolic disorders, known immunodeficiency disorders, malignant tumors, or other serious systemic illnesses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of enteric neuronal markers (TuJ1, AchE, NSE);Neuronal cell apoptosis level;Expression levels of methionine metabolism-related enzymes (MAT2A, MAT1A, SAHH);Expression of methionine metabolism-related enzymes;Activation status of JAK/STAT pathway (JAK2, STAT3, and phosphorylation);Nanoplastic accumulation level;Cell proliferation and apoptosis status;Offspring development and intestinal function changes; | — |
Countries
China
Contacts
Public ContactShang Xianhui
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed